Latest Administration News

Perpetual Limited reported a steady underlying profit for FY25, achieving significant cost savings while navigating asset management outflows and advancing the sale of its Wealth Management division.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Perpetual Limited reported a resilient FY25 with a slight dip in underlying profit, offset by strong asset growth and progress on its Simplification Program and Wealth Management sale.

Lifestyle Communities reported a significant statutory loss for FY25, driven by legal provisions and asset write-downs, yet signs of recovery emerged in the second half with improved sales and cash flow.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Australian Ethical Investment Limited has delivered a standout FY25 with record funds under management and significant profit growth, setting the stage for its next growth phase.

Australian Ethical Investment Limited reported a robust 68% rise in net profit after tax and a 34% increase in funds under management for FY25, driven by strong organic growth and the Altius acquisition. The company declared a fully franked final dividend of 9 cents per share, underscoring confidence in its growth trajectory.

GLG Corp Ltd reported a reduced net loss of USD 1.35 million for FY2025, improving margins and operational efficiency despite a slight revenue decline. The company closed its Malaysian manufacturing plant and foresees challenges ahead in FY2026.

Count Limited reported a robust FY2025 with significant revenue and earnings growth, driven by strategic acquisitions and operational efficiencies. The company’s expansion in wealth management and services segments highlights its evolving market leadership.

Way2VAT has reported a robust first half of FY25, posting a 43% increase in revenue alongside key contract expansions and improved operational efficiency.

ImpediMed Limited has posted a 23% increase in revenue for the 2025 financial year, yet its net loss widened by 17%, with no dividends declared. The company’s financials, audited by Ernst & Young, reveal a complex picture of growth paired with escalating costs.